Abstract
A trial of the flavonoid Catergen (Zyma) has been undertaken in 11 adults with osteogenesis imperfecta (OI). The only significant clinical or metabolic side-effects were severe headaches, which necessitated the withdrawal of 3 patients from the trial. Patient compliance in terms of palatability of Catergen was good, and 3 of the 8 patients who completed the trial experienced subjective improvement. After 6 months' treatment with Catergen, the abnormally narrow collagen fibrils found in the osteoid region in a pretreatment bone biopsy specimen from a middle-aged man with the common type 1 (autosomal dominant) form of OI showed a significant reversion to normal diameters. Post-treatment specimens from his 2 affected sons, who exhibited the same defect, showed a similar but less marked response.
| Original language | Undefined |
|---|---|
| Pages (from-to) | 907-910 |
| Number of pages | 4 |
| Journal | South African Medical Journal |
| Volume | 66 |
| Issue number | 24 |
| Publication status | Published - 1984 |
Keywords
- catechin
- catechol
- flavonoid, adverse drug reaction
- bone
- clinical article
- drug efficacy
- drug safety
- drug therapy
- headache
- human
- intoxication
- nervous system
- neurotoxicity
- oral drug administration
- osteogenesis imperfecta
- priority journal
- therapy, Adult
- Benzopyrans
- Bone and Bones
- Catechin
- Collagen
- Female
- Human
- Male
- Middle Age
- Osteogenesis Imperfecta
- Support, Non-U.S. Gov't
- Time Factors